Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.47 |
| ▸ | PPARA | Q07869 | 14/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228595 | 0.91 | FFAR1 (0.57) | PPARGPPARAFFAR1 | |
| SCHEMBL5228786 | 0.91 | PPARA (0.51) | PPARGPPARAFFAR1 | |
| SCHEMBL5437130 | 0.85 | PPARG (0.64) | PPARGPPARA | |
| SCHEMBL5228982 | 0.84 | PPARG (0.55) | PPARGPPARAFFAR1TP53MAPT | |
| SCHEMBL5232928 | 0.84 | FFAR1 (0.54) | PPARGPPARAFFAR1 | |
| SCHEMBL5224993 | 0.82 | KDR (0.58) | PPARGPPARA | |
| SCHEMBL5223600 | 0.82 | FFAR1 (0.63) | PPARGPPARAFFAR1 | |
| SCHEMBL14361101 | 0.82 | PPARA (0.53) | PPARGPPARA | |
| SCHEMBL5231084 | 0.81 | PPARG (0.47) | PPARGPPARAFFAR1MAPT | |
| SCHEMBL5229727 | 0.81 | PPARG (0.51) | PPARGPPARAFFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | CRYSTAL GENOMICS, INC. (KR) | 2007-11-01 | — | — | US | disclosed |
| EP-1778654-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | Crystalgenomics, Inc. (KR) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006006832-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | CRYSTALGENOMICS, INC. (KR) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | SULT2A1, SPTLC2, SGMS2 | PPARG 399/4885PPARA 190/4885FFAR1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.